This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): BMS-753493
Description: BMS753493 is a folate-targeted anti-cancer therapy.BMS753493 is a folate receptor-targeted epothilone that contains an epothilone moiety linked to a single folate molecule. Mediated through the folate moiety, this agent delivers the antimitotic epothilone component into cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the epothilone moiety induces microtubule polymerization and stabilizes microtubules against depolymerization, resulting in the inhibition of mitosis and cellular proliferation.
Deal Structure: In January 2006, Endocyte announced it licensed to Bristol-Myers Squibb Endocytes vitamin-targeting technology to target Bristol-Myers Squibbs proprietary epothilone cancer chemotherapeutic agents. The license is a result of an ongoing collaborative research effort between the two companies to create novel folate conjugates of Bristol-Myers Squibbs proprietary epothilone compounds.
Under the terms of the license, Endocyte will receive a $3 million license payment, milestone payments and royalties on the sales of any products that result from the license. Bristol-Myers Squibb is responsible for all development, manufacturing, registration and marketing of the resulting products.
In 2010, Bristol-Myers Squibb terminated their agreement with Endocyte, entered in December 2005. As a result, Endocyte does not expect to receive additional milestones or ryalties associated with the epothione compounds.
Additional information available to subscribers only: